Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Precision Medicine and Biomarkers

Clinical or translational studies aimed at optimally matching patients to treatments, including biomarkers and resistance mechanisms

SUBMIT TO JOURNAL
Latest in Precision Medicine and Biomarkers
January 09 2025
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Tharani Krishnan, Joao Paulo Solar Vasconcelos et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with treatment outcomes ...
January 08 2025
Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung Cancer
Jessica Loo, Marc Robbins et al.
Virtual staining for digital pathology has great potential to enable spatial biology research, improve efficiency and reliability in the clinical workflow, as well as conserve tissue samples in a nondestructive manner. In this study, we demonstrate the feasibility of generating virtual stains for hematoxylin and eosin ...
January 06 2025
Serially quantifying TERT rearrangement breakpoints in circulating tumor DNA enables minimal residual disease monitoring in patients with neuroblastoma
Jan F. Hollander, Annabell Szymansky et al.
January 06 2025
Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
Mariko Sasaki, Daiki Kato et al.
The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex is divided into three subcomplexes: cBAF, PBAF, and ncBAF. Constituent genes (e.g., SMARCB1, SMARCA4, SMARCA2, and SS18) of the SWI/SNF complex often harbor genetic abnormalities in various cancers. Previously, we found that histone ...
December 31 2024
Deep Learning Predicts Subtype Heterogeneity and Outcomes in Luminal A Breast Cancer Using Routinely Stained Whole Slide Images
Nikhil Cherian Kurian, Peter H. Gann et al.
December 31 2024
A cost-effective two-step approach for multi-cancer early detection in high-risk populations
Shuaipeng Geng, Shiyong Li et al.
In population-wide cancer screening, three key issues need to be focused on: number of cancer cases identified, number of false positives, and cost. OncoSeek is a multi-cancer early detection (MCED) test using seven protein tumor markers (PTMs) and artificial intelligence (AI). SeekInCare is an MCED test that integrates ...
December 27 2024
Identification of ncRNA Biomarkers in Non–Small Cell Lung Cancer to Address Racial Disparities
Lu Gao, Pushpa Dhilipkannah et al.
Lung cancer significantly impacts mortality, with African Americans (AA) showing higher rates than White Americans (WA). ncRNAs play a crucial role in lung tumorigenesis. To identify ncRNA biomarkers associated with racial disparities in lung cancer, we used droplet digital PCR to examine 93 lung cancer–associated ncRNAs ...
December 26 2024
Clinical proteomics reveals vulnerabilities in non-invasive breast ductal carcinoma and drives personalized treatment strategies
Georgia Mitsa, Livia Florianova et al.
Ductal carcinoma in situ (DCIS) is the most common type (80%) of non-invasive breast lesions in women. The lack of validated prognostic markers, limited patient numbers, and variable tissue quality have a significant impact on diagnosis, risk stratification, patient enrolment, and the results of clinical studies. Here, we ...
December 26 2024
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
Maj K. Kjeldsen, Morten Jørgensen et al.
The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond ...
December 23 2024
PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer
Tsz Tung Kwong, Hao Hao Deng et al.
Arginine deprivation using arginase emerges as a potential cancer treatment approach, as some cancers have been found to be arginine-auxotrophic, relying on exogenous arginine for their growth. In this study, we evaluated the combination of a PEGylated recombinant human arginase (PEG-BCT-100), which is currently ...
View all Precision Medicine and Biomarkers articles

Topics in Precision Medicine and Biomarkers

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept